Design Therapeutics DSGN
NASDAQ DSGN
$12.24 -0.33 (-2.63%)
At close: Oct 1, 2026 · 4:00 PM EDT

Design Therapeutics (DSGN) Liabilities and Shareholders Equity (2020 - 2026)

Updated

Design Therapeutics' Liabilities and Shareholders Equity was $215.13 million in Q2 2026, down 3.5% from $222.89 million a year earlier and down 6.6% from the prior quarter.

Analysis

Design Therapeutics (DSGN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

At the end of FY2025, Liabilities and Shareholders Equity at Design Therapeutics came in at $226.2 million, down 10.3% from FY2024.

  • Liabilities and Shareholders Equity has now declined for four consecutive years, though with a five-year compound annual growth rate of 44.0% (FY2020 to FY2025).
  • In earlier years, Liabilities and Shareholders Equity was $252.09 million in FY2024 (-13.0%), $289.64 million in FY2023 (-15.1%), $341.14 million in FY2022 (-12.7%) and $390.56 million in FY2021 (+969.6%).
  • Quarterly Liabilities and Shareholders Equity has moved between $211.77 million (Q3 2025) and $400.35 million (Q3 2021) over five years.
  • Compared with a year earlier, Liabilities and Shareholders Equity has declined for 18 straight quarters, with an average decline of 11.7% over the last eight quarters.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q4 2021 (growth of 969.6%); the worst was Q3 2025 (a decline of 19.1%).
  • Per Business Quant data, DSGN's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $230.44 million (Q1 2026), $226.2 million (Q4 2025) and $211.77 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Design Therapeutics 786.63 Mn -69.40 Mn - 215.13 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 215.13 Mn
Mar 31, 2026 230.44 Mn
Dec 31, 2025 226.20 Mn
Sep 30, 2025 211.77 Mn
Jun 30, 2025 222.89 Mn
Mar 31, 2025 237.48 Mn
Dec 31, 2024 252.09 Mn
Sep 30, 2024 261.63 Mn
Jun 30, 2024 269.58 Mn
Mar 31, 2024 278.79 Mn
Dec 31, 2023 289.64 Mn
Sep 30, 2023 299.87 Mn
Jun 30, 2023 311.63 Mn
Mar 31, 2023 324.74 Mn
Dec 31, 2022 341.14 Mn
Sep 30, 2022 354.57 Mn
Jun 30, 2022 367.93 Mn
Mar 31, 2022 378.80 Mn
Dec 31, 2021 390.56 Mn
Sep 30, 2021 400.35 Mn
API Access

Design Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=DSGN&period=max&api_key=YOUR_API_KEY